Ask AI
ProCE Banner Activity

CE

Personalized Treatment in EGFR-Mutated NSCLC: Applying the Latest Clinical Evidence to Address Barriers and Improve Quality of Care

Video

In this certified on-demand webcast, an expert discusses the importance of biomarker testing in NSCLC to identify EGFR and other actionable mutations, guide targeted treatment selection across disease stages, and manage toxicities with newer agents such as osimertinib, amivantamab-based regimens, and datopotamab deruxtecan.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: February 10, 2026

Expiration: August 09, 2026

Share

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with advanced NSCLC, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Conduct testing to enable the early detection and identification of actionable EGFR mutations, interpret the results, and determine implications for NSCLC treatment planning

  • Differentiate the mechanisms of action of tyrosine kinase inhibitors, bispecific antibodies, and other precision-targeted agents approved for EGFR-mutated NSCLC

  • Evaluate the latest clinical data to guide treatment selection for EGFR-mutated NSCLC, including patient-specific considerations, emphasizing strategies to improve outcomes and patient quality of life

  • Apply the latest evidence-based strategies to monitor, prevent, and manage AEs with EGFR-targeted therapies, including the use of prophylactic dermatologic regimens to reduce the incidence of skin and nail adverse reactions

Disclosure

ProCE LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Val R. Adams, PharmD, FCCP, FHOPA, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC dba Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 10, 2026, through August 09, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC dba Decera Clinical Educaiton. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-016-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.